Literature DB >> 19393107

Bugs, biofilms, and resistance in cystic fibrosis.

Jane C Davies1, Diana Bilton.   

Abstract

Bacteria infect the respiratory tract early in the course of cystic fibrosis disease, often fail to be eradicated, and together with an aggressive host inflammatory response, are thought to be key players in the irreversible airway damage from which most patients ultimately die. Although incompletely understood, certain aspects of the cystic fibrosis airway itself appear to favor the development of chronic modes of survival, in particular biofilm formation; this and the development of antibiotic resistance following exposure to multiple antibiotic courses lead to chronic, persistent infection. In addition to the common cystic fibrosis pathogens, such as Staphylococcus aureus, Haemophilus influenzae, and Pseudomonas aeruginosa, several newer species are becoming more common. Furthermore, new molecular techniques have led to the identification of multiple different organisms within respiratory secretions, many of which are not cultured with conventional tools. Future work should aim to develop clinically applicable methods to identify these and to determine which have the potential to impact pulmonary health. We outline the basic tenets of infection control and treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19393107     DOI: 10.4187/aarc0492

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  40 in total

1.  Rothia aeria acute bronchitis: the first reported case.

Authors:  J Michon; D Jeulin; J-M Lang; V Cattoir
Journal:  Infection       Date:  2010-04-01       Impact factor: 3.553

2.  Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.

Authors:  Michael W Konstan; Patrick A Flume; Matthias Kappler; Raphaël Chiron; Mark Higgins; Florian Brockhaus; Jie Zhang; Gerhild Angyalosi; Ellie He; David E Geller
Journal:  J Cyst Fibros       Date:  2010-11-12       Impact factor: 5.482

3.  Visualizing the Mechanism of Epoxide Hydrolysis by the Bacterial Virulence Enzyme Cif.

Authors:  Christopher D Bahl; Kelli L Hvorecny; Christophe Morisseau; Scott A Gerber; Dean R Madden
Journal:  Biochemistry       Date:  2016-01-22       Impact factor: 3.162

4.  Nebulized thiocyanate improves lung infection outcomes in mice.

Authors:  J D Chandler; E Min; J Huang; D P Nichols; B J Day
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

5.  Purification, crystallization and preliminary X-ray diffraction analysis of Cif, a virulence factor secreted by Pseudomonas aeruginosa.

Authors:  Christopher D Bahl; Daniel P MacEachran; George A O'Toole; Dean R Madden
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-12-25

Review 6.  Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review.

Authors:  M C Gaspar; W Couet; J-C Olivier; A A C C Pais; J J S Sousa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-26       Impact factor: 3.267

7.  Alginate lyase exhibits catalysis-independent biofilm dispersion and antibiotic synergy.

Authors:  John W Lamppa; Karl E Griswold
Journal:  Antimicrob Agents Chemother       Date:  2012-10-15       Impact factor: 5.191

8.  Recycling of peptidyl-tRNAs by peptidyl-tRNA hydrolase counteracts azithromycin-mediated effects on Pseudomonas aeruginosa.

Authors:  Julia Gödeke; Christian Pustelny; Susanne Häussler
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

Review 9.  The pathophysiology of bronchiectasis.

Authors:  Paul T King
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-11-29

10.  Longitudinal survey of Staphylococcus aureus in cystic fibrosis patients using a multiple-locus variable-number of tandem-repeats analysis method.

Authors:  Hoang Vu-Thien; Katia Hormigos; Gaëlle Corbineau; Brigitte Fauroux; Harriet Corvol; Didier Moissenet; Gilles Vergnaud; Christine Pourcel
Journal:  BMC Microbiol       Date:  2010-01-27       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.